West Pharmaceutical SVP granted RSUs and options

West Pharmaceutical Services reported that SVP, General Counsel and Corporate Secretary Norman D. Finch Jr. received equity awards.

Rhea-AI Filing Summary

West Pharmaceutical Services reported that SVP, General Counsel and Corporate Secretary Norman D. Finch Jr. received equity awards. He was granted 1,285 restricted stock units and 3,057 stock options, each with an exercise right to buy common shares. Both the restricted stock units and options vest in four equal annual installments beginning on March 1, 2027.

Insider Trade Summary

Grant/Award: 4,342 shares

Grant/Award 2 txns

Insider Finch Norman D. Jr.

Role SVP, GC & Corporate Secretary

Type	Security	Shares	Price	Value
Grant/Award	Rst. Stock Unit	1,285	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	3,057	$0.00	$0.00

Holdings After Transaction: Rst. Stock Unit — 1,285 contracts (Direct); Stock Option (Right to Buy) — 3,057 contracts (Direct)

Footnotes (3)

1. F1. Each restricted stock unit represents a contingent right to receive one share of WST common stock.
2. F2. The restricted stock units vest in four equal annual installments beginning on March 1, 2027.
3. F3. The stock option vests in four equal annual installments beginning on March 1, 2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did West Pharmaceutical Services (WST) disclose in this Form 4 for Norman D. Finch Jr.?

West Pharmaceutical Services reported that executive Norman D. Finch Jr. received equity awards. He was granted restricted stock units and stock options as part of his compensation, increasing his derivative-based holdings in the company’s common stock under a structured vesting schedule.

How many restricted stock units did Norman D. Finch Jr. receive from West Pharmaceutical (WST)?

Norman D. Finch Jr. received 1,285 restricted stock units. Each unit represents a contingent right to receive one share of West Pharmaceutical common stock, subject to time-based vesting conditions over four years beginning March 1, 2027, aligning his interests with long-term shareholder value.

What stock options were granted to Norman D. Finch Jr. by West Pharmaceutical (WST)?

He was granted stock options covering 3,057 shares of common stock. These options were awarded with a grant price of $0.00 in the filing, and they vest in four equal annual installments starting on March 1, 2027, contingent on continued service.

When do Norman D. Finch Jr.’s restricted stock units at West Pharmaceutical (WST) vest?

The restricted stock units vest in four equal annual installments beginning on March 1, 2027. This means one-quarter of the units becomes deliverable each year over four years, assuming continued employment and satisfaction of the award’s standard conditions.

What is the vesting schedule for the stock options granted to Norman D. Finch Jr. at West Pharmaceutical (WST)?

The stock options vest in four equal annual installments starting March 1, 2027. Each year, one-quarter of the option grant becomes exercisable, creating a long-term incentive that encourages ongoing service and alignment with the company’s multi-year performance.

Does this West Pharmaceutical (WST) Form 4 show any insider share sales by Norman D. Finch Jr.?

No insider share sales are shown; the filing only reports acquisitions. It details grants of restricted stock units and stock options to Norman D. Finch Jr., with no dispositions or open-market sales reported in the provided transaction summary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 11:36 AM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Finch Norman D. Jr.

(Last) (First) (Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON PA 19341

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, GC & Corporate Secretary

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Rst. Stock Unit	(1)	03/01/2026		A		1,285		(2)	(2)	Common Stock	1,285	$0	1,285	D
Stock Option (Right to Buy)	$254.34	03/01/2026		A		3,057		(3)	03/01/2036	Common Stock	3,057	$0	3,057	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of WST common stock.

2. The restricted stock units vest in four equal annual installments beginning on March 1, 2027.

3. The stock option vests in four equal annual installments beginning on March 1, 2027.

	/s/ Caitlin Hippeli, as an agent for Norman Finch	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.